Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer

Prostate cancer remains the most common type of cancer among men in the United States. Treatment for metastatic prostate cancer has improved significantly over the years with more and more agents improving overall survival. This review will address the pathophysiology of prostate cancer followed by...

Full description

Saved in:

Bibliographic Details
Published in:	Research and reports in urology Vol. 6; no. default; pp. 97 - 105
Main Authors:	Zobniw, Chrystia M, Causebrook, Alanna, Fong, Mei Ka
Format:	Journal Article
Language:	English
Published:	England Taylor & Francis Ltd 01-01-2014 Dove Medical Press
Subjects:	Adrenal glands Androgens Biosynthesis Cancer therapies Chemotherapy Cytochrome Feedback Gene expression Hormones Immunotherapy Metastasis Pharmacy Prostate cancer Review Testosterone Vaccines United States > US pipeline sipuleucel-T glucocorticoid receptor radium-223 dichloride CYP17 drug resistance enzalutamide
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Prostate cancer remains the most common type of cancer among men in the United States. Treatment for metastatic prostate cancer has improved significantly over the years with more and more agents improving overall survival. This review will address the pathophysiology of prostate cancer followed by the mechanism of action and the pharmacokinetic properties of abiraterone. The review will also discuss the role of abiraterone in the treatment of metastatic castrate-resistant prostate cancer.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	2253-2447 2253-2447
DOI:	10.2147/rru.s29003